Abstract
An archipelago country such as Indonesia has a different beginning of the outbreak, therefore the management of epidemics not uniform. For this reason, the results in the data of confirmed cases COVID-19 to fluctuate and difficult to predict. We use the data-driven SIR model to analyze the dynamics and behavior of the evolution of the disease. We run the data-driven SIR model gradually and found that there are shifting of the peak and the distance of saturation point. We found that a transmission acceleration of the outbreak occurring in Indonesia where it could be seen from increasing of the time the saturation and the confirmed cases. It is finally argued that a new parameter can be used to guidance the condition when the new normal begins.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
this article is epidemy model of covid-19 with Indonesia data
Funding Statement
This research is funded by PTPSW-BPPT for fiscal years 2019/2020
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
the data is obtained form Satuan Gugus tugas covid-19 BNPB Indonesia
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.